Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
26 Mar 24
8-K
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
6 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
31 Jan 24
S-8
Registration of securities for employees
2 Jan 24
8-K
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuardTM Neuroprotection System
20 Dec 23
8-K
Regulation FD Disclosure
27 Nov 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
InspireMD Reports Third Quarter 2023 Financial Results and Provides
6 Nov 23
8-K
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS
1 Nov 23
8-K
Regulation FD Disclosure
12 Oct 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
S-8
Registration of securities for employees
6 Oct 23
8-K
Amendments to Articles of Incorporation or Bylaws
13 Sep 23
8-K
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
31 Aug 23
8-K
InspireMD Reports Second Quarter 2023 Financial Results and Provides
8 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
DEFA14A
Additional proxy soliciting materials
28 Jul 23
DEF 14A
Definitive proxy
28 Jul 23
8-K
Departure of Directors or Certain Officers
21 Jul 23
PRE 14A
Preliminary proxy
18 Jul 23
8-K
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
26 Jun 23
424B3
Prospectus supplement
2 Jun 23
EFFECT
Notice of effectiveness
2 Jun 23
CORRESP
Correspondence with SEC
31 May 23
D
$42.17 mm in equity / options / securities to be acquired, sold $42.17 mm, 18 investors
30 May 23
UPLOAD
Letter from SEC
30 May 23
S-3
Shelf registration
23 May 23
8-K
Regulation FD Disclosure
23 May 23
S-8
Registration of securities for employees
17 May 23
8-K
InspireMD Reports First Quarter 2023 Financial Results and Provides
16 May 23
8-K
InspireMD Announces Private Placement of Up to $113.6 Million
15 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
30 Mar 23
8-K
InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer
20 Mar 23
Latest ownership filings
SC 13G/A
Rosalind Advisors, Inc.
25 Apr 24
SC 13G/A
Rosalind Advisors, Inc.
14 Feb 24
SC 13G
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
4
Thomas J Kester
25 Jan 24
4
Patrick Verta
25 Jan 24
4
Shane Thomas Gleason
25 Jan 24
4
Andrea Tommasoli
25 Jan 24
4
Kathryn Arnold
25 Jan 24
4
Craig Shore
25 Jan 24
4
GARY S ROUBIN
25 Jan 24
4
Marvin Slosman
25 Jan 24
4
Paul Stuka
25 Jan 24
4
MICHAEL BERMAN
25 Jan 24
4
MICHAEL BERMAN
11 Jan 24
4
Kathryn Arnold
11 Jan 24
4
Thomas J Kester
11 Jan 24
4
GARY S ROUBIN
11 Jan 24
4
GARY S ROUBIN
4 Dec 23
3
Patrick Verta
10 Oct 23
4
MICHAEL BERMAN
4 Oct 23
4
Kathryn Arnold
4 Oct 23
4
GARY S ROUBIN
4 Oct 23
4
Thomas J Kester
4 Oct 23
4
Shane Thomas Gleason
30 Aug 23
4
GARY S ROUBIN
5 Jul 23
4
Thomas J Kester
5 Jul 23
4
MICHAEL BERMAN
5 Jul 23
4
Kathryn Arnold
5 Jul 23
SC 13D
Shore Craig
16 Jun 23
SC 13G
Rosalind Advisors, Inc.
8 Jun 23
SC 13G
Soleus Private Equity Fund III, L.P.
24 May 23
SC 13G
Marshall Wace North America L.P.
22 May 23
4
Marvin Slosman
19 May 23
4
Craig Shore
19 May 23
4
Paul Stuka
19 May 23
4
Shane Thomas Gleason
19 May 23
4
MICHAEL BERMAN
19 May 23
4
Andrea Tommasoli
19 May 23
4
Thomas J Kester
19 May 23